Printer Friendly

Regen BioPharma files US patent application.

M2 EQUITYBITES-May 29, 2015-Regen BioPharma files US patent application


It was reported on Thursday that Regen BioPharma, a biotechnology company, has filed a United States patent application covering mRNA delivered tumour antigens to dendritic cells as a means of inducing tumour immunity.

The current work is based on the firm's Cancer Immunotherapy Platform. This patent application includes intellectual property that offers a means of specifically inducing dendritic cells to internally generate tumour antigens, a process expected to be more effective than exogenously administering antigens to dendritic cells. The new patent application takes advantage of innovations in the field of gene expression that allow for mRNA transfection in to cells.

Thomas Ichim, PhD, Chief Scientific Officer of Regen, said, 'The dendritic cell is the most potent stimulator of the immune response, and controls whether T cells will be activated to kill tumors, or will be suppressed. Regen has been highly focused on understanding and manipulating the biology of dendritic cells in order to develop highly potent cancer immunotherapeutics.'

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 29, 2015
Previous Article:ISSI updates delay in Special Meeting of Stockholders in connection with acquisition proposal by Cypress.
Next Article:Celsion Corporation anticipates USD8m from at-the-market registered direct offering.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters